Supplementary section

Supplementary Table 1 Baseline clinical characteristics

	Tofacitinib 10 mg BID N=15	**Placebo N=14**
Female sex, n	14	12
Age in years, mean (SD)	53.5 (9.2)	53.1 (14.3)
White race, n	10	13
Weight in kg, mean (SD)	96.2 (22.5)	86.5 (20.9)
Body mass index (kg/m^2), mean (SD)	34.8 (8.9)	32.4 (8.1)
Height in cm, mean (SD)	166.8 (8.8)	163.5 (7.3)
RF+, n (%)	15 (100)	14 (100)
Anti-CCP+, n (%)	12 (80.0)	8 (57.1)
Primary diagnosis* of RA, n	15	14
Disease duration (years), mean (range)	12.2 (0.6-33.2)	5.5 (0.6-19.7)
Tender joint count, mean (SD)	36.87 (15.46)	28.64 (17.15)
Swollen joint count, mean (SD)	22.00 (15.80)	16.86 (11.04)
Physician Global Assessment, mean (SD)	63.54 (25.96)	47.71 (26.55)
Patient Global Assessment, mean (SD)	64.94 (28.61)	53.29 (27.65)
Patient Pain Assessment, mean (SD)	69.05 (15.49)	55.64 (11.67)
HAQ-DI†, mean (SD)	1.76 (0.48)	1.40 (0.62)
DAS28-4(ESR), mean (SD)	6.55 (0.98)	6.32 (1.01)
CRP (mg/L), mean (SD)	14.19 (12.78)	10.54 (9.96)

*Based on MedDRA (version 14.1) coding dictionary preferred terms.
Body mass index was calculated as weight/height^2
†Time (years) from first diagnosis to Day 1 of study

ACR, American College of Rheumatology; BID, twice daily; BMI, body mass index; CCP, cyclic citrullinated peptide; CRP, C- reactive protein; ESR, erythrocyte sedimentation rate; HAQ-DI, Health Assessment Questionnaire-Disability Index; MedDRA, Medical Dictionary for Regulatory Activities; RA, rheumatoid arthritis; RF, rheumatoid factor; SD, standard deviation

Supplementary Table 2 Treatment-emergent adverse events (all causalities)

	Tofacitinib 10 mg BID	**Placebo**
Number of patients	15	14
Patients evaluable for adverse events	15	14
Number of adverse events	27	13
Patients with adverse events, no. (%)	7 (46.7)	10 (71.4)
Patients with serious adverse events	0	0
Patients with severe adverse events, no. (%)	1 (6.7)	0
Patients with serious infection events	0	0
Number of discontinuations, total	0	0
Patients discontinued due to adverse events	0	0
Patients with dose reduced or temporary discontinuation due to adverse events, no. (%)	0	1 (7.1)
Number of deaths	0	0

Serious adverse events were based on the investigator's assessment.

BID, twice daily